• AZ recruits ImaginAb in CD8 ImmunoPET deal pharmatimes
    March 31, 2020
    AstraZeneca has revealed plans to signed a multi-year non-exclusive license agreement with ImaginAb, in order to license the latter’s ImaginAb’s CD8 ImmunoPET technology.
PharmaSources Customer Service